$29.65
Value $1.6B
ASTH and UNP stock compared: price, dividend, valuation and results, from SEC filings.
$29.65
Value $1.6B
$300.90
Value $179B
Astrana Health (ASTH) has a market value of $1.6B and Union Pacific (UNP) $179B. Over the last year, with dividends, ASTH moved +41.0% and UNP +39.0%. The P/E is 31.0 for ASTH and 23.4 for UNP. Dividend yield: ASTH 0.10%, UNP 1.85%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ASTH$1.6B
UNP$179B
UNP is 108 times ASTH
Revenue, 12 months
ASTH$3.9B
UNP$26.4B
UNP is 6.7 times ASTH
Net income, 12 months
ASTH$53M
UNP$7.6B
UNP is 143 times ASTH
Operating margin
ASTH3.1%
UNP40.1%
37.0 points apart
ROIC
ASTH4.5%
UNP16.1%
11.6 points apart
P/E
ASTH31.0
UNP23.4
ASTH is 1.3 times UNP
Dividend yield
ASTH0.1%
UNP1.8%
1.8 points apart
5-year return
ASTH-74.7%
UNP+40.3%
115.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ASTH-74.7%
UNP+40.3%
| Period | ASTHWith dividends | UNPWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +41.0%Price +41.0% | +39.0%Price +36.2% |
| 3 years since November 17, 2023 | -15.6%-5.5% a yearPrice -15.6% | +46.6%+13.6% a yearPrice +37.3% |
| 5 years since November 17, 2021 | -74.7%-24.1% a yearPrice -74.7% | +40.3%+7.0% a yearPrice +25.5% |
| 10 years since November 18, 2016 | +641.2%+22.2% a yearPrice +641.3% | +275.0%+14.1% a yearPrice +201.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ASTHAstrana HealthUNPUnion Pacific
| Price | $29.65 | $300.90 |
|---|---|---|
| Market value | $1.6B | $179B |
| Enterprise value (EV) | $2.2B | $207B |
| P/E | 31.0 | 23.4 |
| P/E, 5-year median | 35.0 | 20.6 |
| P/B | 1.9 | 8.1 |
| EV/EBIT | 18.0 | 19.6 |
| Free cash flow yield | 6.0% | 3.8% |
| Revenue, 12 months | $3.9B | $26.4B |
|---|---|---|
| Net income, 12 months | $53M | $7.6B |
| Free cash flow, 12 months | $99M | $6.7B |
| Earnings per share, 12 months | $0.96 | $12.83 |
| Revenue growth, year on year | 56.4% | 1.1% |
| Revenue growth a year, past | +35.9%over 5 years | +4.6%over 5 years |
| EPS growth a year, past | -14.5%over 5 years | +8.7%over 5 years |
| Gross margin | 11.0% | – |
|---|---|---|
| Operating margin | 3.1% | 40.1% |
| Net margin | 1.4% | 28.9% |
| ROIC | 4.5% | 16.1% |
| ROE | 6.6% | 38.9% |
| Cash | $396M | $2.2B |
|---|---|---|
| Total debt | $977M | $31.1B |
| Net debt / EBITDA | 3.2 | 2.2 |
| Interest cover | 1.9× | 8.3× |
| Dividend yield | 0.1% | 1.8% |
|---|---|---|
| Dividend per share, 12 months | $0.03 | $5.56 |
| Dividend growth a year, past | – | +7.0%over 5 years |
| Buyback yield | 1.6% | 1.5% |
| Shareholder yield | 1.7% | 3.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Union Pacific ($179B) is about 108.3 times Astrana Health ($1.6B), at today's prices.
Since November 18, 2016, ASTH's price moved +641.3% and UNP's +201.4%. With dividends: ASTH +641.2% (+22.2% a year), UNP +275.0% (+14.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.10% for Astrana Health and 1.85% for Union Pacific. Over the last twelve months they paid $0.03 and $5.56 per share.
At today's price, the P/E is 31.0 for ASTH and 23.4 for UNP. The median of the last five years was 35.0 and 20.6, which shows where each stands against its own past.
Over the last twelve months, the net margin was 1.4% for Astrana Health and 28.9% for Union Pacific, and the operating margin 3.1% and 40.1%. Revenue was $3.9B and $26.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.